A comprehensive study on sitagliptin in the treatment of Type-II Diabetes
QIS Group of Institutions, QIS College of Pharmacy; Prakasam (Dt.); Ongole
Research Article
World Journal of Biology Pharmacy and Health Sciences; 2024, 20(03), 120–129.
Article DOI: 10.30574/wjbphs.2024.20.3.0988
Publication history:
Received on 26 October 2024; revised on 04 December 2024; accepted on 06 December 2024
Abstract:
Sitagliptin is an oral antihyperglycemic drug classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor; commonly used in the treatment of type 2 diabetes. It works by promoting insulin secretion and decreasing glucagon levels through the inhibition of incretin degradation in a glucose-dependent manner. As of 2013; it was the second-highest selling medication in the United States. This review highlights various analytical techniques for the quantification of sitagliptin; either alone or in combination with other agents. These methods include spectrometry; high-performance liquid chromatography (HPLC); liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS/MS); liquid chromatography-mass spectrometry (LC-MS); capillary electrophoresis (CE); ultra-performance liquid chromatography (UPLC); high-performance thin-layer chromatography (HPTLC); and gas chromatography-mass spectrometry (GC-MS).
Keywords:
Sitagliptin; Analytical methods; Type-2 diabetes; HPLC, LC-MS; CE; LC-ESI-MS/MS; UPLC.
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0